Scorpion Therapeutics to Present Preclinical Data for Potential Best-in-Class Mutant-Selective PI3Kα Inhibitor at San Antonio Breast Cancer Symposium

BOSTON–(BUSINESS WIRE)–Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced that it will present preclinical data on STX-478, its potential best-in-class mutant-selective PI3Kα inhibitor, in a poster session at San Antonio Breast Cancer Symposium (“SABCS”) in San Antonio, Texas, taking place December 6 – 10, 2022. STX-478 is a highly selective, allosteric and CNS-penet
Click here to view original post